Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-321 in HPV 16+ Advanced Malignancies
NCT04672980Phase 1Terminated
- Sponsor
- Rubius Therapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Dendritic Cell Vaccines, Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of RTX-321 in Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC) and anal cancer (2 arms), sponsored by Rubius Therapeutics. Primary endpoints: Safety Assessment by rate of Adverse Events up to 30 months and Dose limiting toxicities up to 30 months. Started Apr 2021; status: terminated.
02
Drugs
RTX-321
03
Conditions
Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)anal cancer
Beyond the preview
Go deeper on NCT04672980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672980.